This paper is the BioPhorum response to the recent ICH Q14 and Q2(R2) consultation. Overall, the first-draft guidelines seen by the team need to be less detailed in the main body of the documents but more specific to analytical methods. The documents must also be consistent throughout (across Q14 and Q2 and between the main body texts and examples). Further, detailed examples are needed for modalities other than small molecules (e.g., biologics, cell and gene therapies, etc.) as the small molecule examples are not relevant in some key respects. In the view of the BioPhorum team, the current documents will not drive a consistent understanding of regulatory expectations and the provision of information by industry to regulators.
Viewing related articles
A member only survey to benchmark industry experience with replication competent AAV testing. The outcome of the survey will help stimulate further discussion of the topic within the workstream.
A BioPhorum member only resource examining the enablers and blockers to the implementation of APC/PA solutions.
Key messages emerging following analysis of the survey are that bridging approaches differ between companies and there is lack of a harmonized approach outside a commercial setting. The Workstream are examining if a guidance paper would be beneficial.
A benchmarking survey prompted by an increase in regulatory questions regarding polysorbate.